Search

Search Constraints

You searched for: Author/Creator Motoya, Satoshi

Search Results

1. Adrenomedullin for biologic‐resistant Crohn's disease: A randomized, double‐blind, placebo‐controlled phase 2a clinical trial. Issue 11 (25th July 2022)

2. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. (July 2022)

3. An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease. Issue 1 (December 2015)

4. Association of Dietary Fatty Acid Intake With the Development of Ulcerative Colitis: A Multicenter Case-Control Study in Japan. Issue 5 (15th April 2021)

5. Caudal type homeobox 2 expression induced by leukocytapheresis might be associated with mucosal healing in ulcerative colitis. Issue 5 (27th April 2017)

6. Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial. Issue 9 (September 2015)

7. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. (June 2021)

8. Efficacy and Safety of Dose Escalation to Adalimumab 80 Mg Every Other Week in Japanese Patients With Crohn's Disease Who Lost Response to Maintenance Therapy: 1873. (October 2015)

9. First Trough Level of Infliximab at Week 2 Predicts Future Outcomes of Induction Therapy in Ulcerative Colitis: A Post‐hoc Analysis of a Multicenter Prospective Randomized Controlled Trial: 1851. (October 2015)

10. Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease. Issue 1 (27th January 2021)